Novartis Oncology

Novartis Oncology

制药业

Basel，Switzerland 275,773 位关注者

Reimagining medicine by transforming cancer

查看职位 关注

关于我们

At Novartis, our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. At Novartis, we focus on five key cancer areas where we have identified patient needs and promise within our portfolio - breast cancer, lung cancer, melanoma, kidney cancer and hematology. As a leader in oncology, Novartis offers a portfolio treating more than 25 conditions worldwide and approximately 30 compounds in development. We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are reimagining medicine. See our community guidelines:https: https://bit.ly/3yAl483

网站
https://www.novartis.com/about/therapeutic-areas/oncology
所属行业
制药业
规模
超过 10,001 人
总部
Basel，Switzerland
类型
上市公司
领域
Research、Innovation、Oncology、Hematology、Immunooncology和Quality

地点

Novartis Oncology员工

查看全部员工

动态

  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    Chronic myeloid leukemia (#CML) is a chronic disease that requires long-term daily therapy. Today’s FDA approval adds another option for people living with CML. ? #ReimaginingMedicine

    查看Novartis US的公司主页，图片
    Novartis US

    101,321 位关注者

    We are proud to announce the FDA approval for adults with newly diagnosed Ph+ chronic myeloid leukemia (#CML) in chronic phase. About 10,000 people each year are diagnosed with chronic myeloid leukemia in the US. With this approval, up to 4 times the number of currently eligible patients will have the opportunity to explore a new treatment. #NovartisNews #ReimaginingMedicine

  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    查看Novartis US的公司主页，图片
    Novartis US

    101,321 位关注者

    Meet Nicole. Like her, many people diagnosed with early #breastcancer face concerns around their cancer coming back, even after achieving remission. Despite adjuvant therapies available to date, many diagnosed with HR+/HER2- stage II or III early breast cancer (eBC) may experience disease recurrence. Today’s FDA approval can help us change these statistics and support patients in navigating life after diagnosis and treatment. We are grateful to people like Nicole, who together with other patients and their loved ones, health care providers, scientists and advocates, participated in the research leading to this approval, helping elevate care, improve outcomes and empower more people diagnosed with eBC. #bcsm #ReimaginingMedicine, together

  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    查看Novartis US的公司主页，图片
    Novartis US

    101,321 位关注者

    Novartis remains committed to promoting health equity and patient-centered care. An example of this is the More Than Just Words initiative, focused on encouraging more productive, empathetic, and unbiased conversations about breast cancer risk, diagnosis and care among health care providers and patients to help improve breast cancer outcomes for Black women. We are bringing this to life with a virtual reality experience that puts us in the shoes of Black women along the breast cancer continuum of care. The VR tool features different scenarios that are based on real-life patient experiences, helping users identify unconscious bias and opportunities for more empathetic care for these patients. Join us at #ASCO2024 to learn more about our efforts in breast cancer health equity. Novartis Oncology

  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    1.2 to 1.5 million people are currently living with chronic myeloid leukemia (CML) worldwide. This new data may offer hope to those living with this difficult disease, advancing our mission to #reimaginemedicine for these patients. #ASCO24

    查看Novartis US的公司主页，图片
    Novartis US

    101,321 位关注者

    This #ASCO2024, we are proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (CML). While advances in CML treatment have enhanced patient outcomes, unmet need remains, with many newly diagnosed patients not meeting treatment goals and many discontinuing or changing treatment due to intolerance. Novartis is committed to working with the CML community to #reimaginemedicine for these patients.

  • Novartis Oncology转发了

    查看Novartis US的公司主页，图片
    Novartis US

    101,321 位关注者

    The Novartis "More Than Just Words" initiative was created in collaboration with a diverse team of experts - including patients, advocates, and healthcare professionals - to address the most pressing issues affecting racial disparities in breast cancer care. Patients, practitioners, health care leaders and members of the industry -- we all have a role to play in helping close the serious gap in care faced by Black women. Let’s work together to address disparities in breast cancer care and #ReimagineMedicine for all. To learn more, visit www.MoreThanJustWords.US or visit us at #ASCO2024. Novartis Oncology

    • 该图片无替代文字
  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    Today we announce the FDA approval of a radioligand therapy for pediatric patients living with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first therapy specifically approved for pediatric patients with this rare cancer, and represents our ongoing commitment to developing the RLT platform across multiple cancer types and treatment settings. https://lnkd.in/e5mgsaBE

    • 该图片无替代文字
  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    #NeuroendocrineTumors (#NETs) are rare types of cancers and the majority (over 60%) originate in the digestive system – these are called gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. The journey to diagnosis is often long and takes a toll on patients’ overall wellbeing. On average, it can take over four years from first onset of symptoms to a final diagnosis, after an extensive medical journey, including several examinations and multiple specialists. Unfortunately, such delays mean that the majority of patients are initially diagnosed with advanced disease. At Novartis, we are dedicated to discovering new ways to improve health outcomes for patient communities with clear unmet needs. Join us at the European Neuroendocrine Tumor Society e.V. (ENETS) congress to learn more about our commitment to exploring first-line treatment options for patients with grade 2 and grade 3 metastatic GEP-NETs. Learn more about #NeuroendocrineCancer during #ENETS24: https://ms.spr.ly/6043c91rP

  • 查看Novartis Oncology的公司主页，图片
    Novartis Oncology

    275,773 位关注者

    GEP-NETs are a diverse and heterogeneous group of tumors with often vague and non-specific symptoms leading to delays in diagnosis. People diagnosed with this type of cancer often express somatostatin receptors on their tumor cells or tumor microenvironment. Radioligand therapy (#RLT) targets these receptors on cancer cells or tumor microenvironment, to destroy or damage them, with the goal of limiting impact on healthy tissues. Hear from us at the European Neuroendocrine Tumor Society e.V. (ENETS) congress as we present findings that explore the use of RLT as a potential first-line treatment in metastatic GEP-NETs. Learn more about radioligand therapies here: https://ms.spr.ly/6042c91Ru #ENETS24

相似主页

查看职位